Use of conventional synthetic and biologic disease-modifying anti-rheumatic drugs in patients with rheumatic diseases contracting COVID-19: a single-center experience

To examine whether patients with inflammatory arthritis (IA) treated with conventional synthetic (cs) disease-modifying anti-rheumatic drugs (DMARDs) and/or biologic (b) DMARDs, could be affected from SARS-CoV-2 infection and to explore the COVID-19 disease course and outcome in this population. Thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Migkos, Michalis P., Kaltsonoudis, Evripidis, Pelechas, Eleftherios, Drossou, Vassiliki, Karagianni, Panagiota G., Kavvadias, Athanasios, Voulgari, Paraskevi V., Drosos, Alexandros A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Observational Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925256/
https://www.ncbi.nlm.nih.gov/pubmed/33655421
http://dx.doi.org/10.1007/s00296-021-04818-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925256/
https://www.ncbi.nlm.nih.gov/pubmed/33655421
http://dx.doi.org/10.1007/s00296-021-04818-2

Ejemplares similares